Reportlinker Adds Global Monoclonal Antibody Market Analysis
NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Monoclonal Antibody Market Analysis
http://www.reportlinker.com/p0324814/Global-Monoclonal-Antibody-Market-Analysis.html
Considered as an indispensable tool in the clinical and biotechnology sector, monoclonal antibodies have testified to be useful in the diagnosis and treatment of many infectious, immune, and neoplastic diseases along with its application in the study of pathogen-host interactions and dialing, detection, & quantification of different molecules. The presence of monoclonal antibodies therapeutics has changed the face of modern medicine in the past decade as they provide innovative and effective therapies for numerous previously refractory illnesses. The number of monoclonal antibodies reaching the marketplace has exponentially increased over the past few years. Various factors such as rapid uptake of monoclonal antibodies, expansion of patient base due to the drug approvals received, and no generics for biological therapies have driven the optimistic market performance of this industry.
According to our new research report "Global Monoclonal Antibody Market Analysis", the global monoclonal antibodies market witnessed an annual growth rate of around 13% during 2008-2009. Presently, large pharmaceutical companies are investing heavily both in developing such drugs internally and acquiring monoclonal antibody candidates from other companies. The inherent specificity and predictability of monoclonal antibodies that reduces the time period of drug development and increases rate of success in preclinical and clinical trials, relative to non-biological 'small molecule' drugs, is further boosting the growth of the industry.
Our report has found that the market is presently dominated by Oncology and AIID applications. However, therapeutic applications of monoclonal antibodies are extending to new therapy areas such as CNS disorders and metabolic disorders. In addition, smaller companies are likely to become more visible as their products move closer to regulatory approvals.
Further, the US, Europe, and Japan are the major geographical markets exhibiting healthy growth rates. Our study indicates that the highest growth rate in the US monoclonal antibody market is likely to be observed for mAbs used for the treatment of cancer, followed by immunologic and inflammatory diseases.
The report provides extensive information and rational analysis of the global monoclonal antibodies market. It has thoroughly examined current market trends; industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years. The report also gives an insight into the segment-wise market trends prevailing at the regional level to provide an overview of developments taking place in these segments across the world.
1. Analyst View
2. Research Methodology
3. Monoclonal Antibodies - An Introduction
4. Market Drivers
4.1 FDA Approvals
4.2 Lack of Competing Biosimilars
4.3 Improvement in Technology
4.4 Treatment Transition
5. Industry Performance
5.1 Market Size and Growth
5.2 Market Application
5.2.1 Oncology
5.2.2 Autoimmune and Inflammatory Disorders (AIID)
5.2.3 Respiratory Diseases
5.2.4 Neurology
5.2.5 Cardiovascular
6. Key Geographical Markets
6.1 US
6.2 Europe
6.3 Japan
6.4 China
6.5 India
7. Key Drugs Analysis
8. Major Acquisitions & Alliances
9. Key Players Profile
9.1 Roche
9.2 Johnson & Johnson
9.3 Abbott
9.4 GSK
9.5 Merck KGaA
9.6 Pfizer
List of Figures:
Figure 5-1: Global - Monoclonal Antibodies Market (Billion US$), 2008 & 2009
Figure 5-2: Global - Monoclonal Antibodies Market by Application (%), 2009
Figure 5-3: Global - Share of Monoclonal Antibodies in Oncology Market (2009)
Figure 5-4: Global - mAbs Oncology Market (Billion US$), 2008 & 2009
Figure 5-5: Global - mAbs Oncology Market by Type (%), 2009
Figure 5-6: Global - mAbs Market for Colorectal Cancer (Billion US$), 2008 & 2009
Figure 5-7: Global - mAbs Market for Breast Cancer (Billion US$), 2008 & 2009
Figure 5-8: Global - mAbs Market for Lymphoma (Billion US$), 2008 & 2009
Figure 5-9: Global - mAbs Market for Leukemia (Million US$), 2008 & 2009
Figure 5-10: Global - mAbs AIID Market (Billion US$), 2008 & 2009
Figure 5-11: Global - mAbs Market for Respiratory Diseases (Billion US$), 2008 & 2009
Figure 6-1: US - Monoclonal Antibodies Market (Billion US$), 2007-2009
Figure 6-2: Europe - Forecast for Monoclonal Antibodies Market by Application (%), 2011
List of Tables:
Table 5-1: Global - mAbs Drugs for Colorectal Cancer by Sales (Million US$), 2009
Table 5-2: Global - mAbs Drugs for Breast Cancer by Sales (Million US$), 2009
Table 5-3: Global - mAbs Drugs for Lymphoma by Sales (Million US$), 2009
Table 5-4: Global - mAbs Drugs for Leukemia by Sales (Million US$), 2009
Table 5-5: Global - mAbs Drugs for AIID
Table 5-6: Global - mAbs Drugs for Respiratory Diseases
Table 5-7: Global - mAbs Drugs for Neurological Disorders
Table 5-8: Global - mAbs Drugs for Cardiovascular Diseases
Table 8-1: Key M&As in Monoclonal Antibodies Market (2005-2010)
To order this report:
Biotechnology Industry: Global Monoclonal Antibody Market Analysis
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article